AMENDMENT TO THE PRICE INQUIRY NO. 19 OF 20 December 2022

Re: provision of services involving the development, manufacture and delivery of an active substance in the form of a modified oligonucleotide – an 18-mer RNA and Technology Transfer to a designated manufacturing site.

This is to inform you that on 20 December 2022 our Price Inquiry was amended as follows:

Before the change	After the change
III. DESCRIPTION OF THE CONTRACT	
III.3.1. Development of specifications for the	III.3.1. Development of a specification for the active
active substance as per ICH Q6 guidelines	substance based on ICH Q6 guideline, omitting
	assessment elements not applicable to
	oligonucleotides
III.3.7. Demonstration of sameness to the	III.3.7. Demonstration of sameness to the reference
reference product Spinraza based on draft	product Spinraza based on draft FDA guideline
FDA guideline PSG_209531 and any other	PSG_209531
regulatory (FDA or EMA) guidelines which	
will be published	
VII. PLACE AND CLOSING DATE FOR SUBMISSION OF QUOTATIONS	
VIII.1. The final deadline for submitting	VIII.1. The final deadline for submitting quotations is
quotations is 04.01.2023 by 11:59 p.m. –	11.01.2023 by 11:59 p.m. – quotations can be sent in
quotations can be sent in electronic format (in	electronic format (in the form of a scan of the signed
the form of a scan of the signed document or	document or document signed with qualified signature)
document signed with qualified signature) to	to the following address:
the following address:	urszula.strzalinska@polpharma.com
adam.obidzinski@polpharma.com	
IX. PREPARATION OF QUOTATIONS	
IX.5. For any matters related to this Price	IX.5. For any matters related to this Price Inquiry,
Inquiry, please contact the Contracting Party,	please contact the Contracting Party, e-mail:
e-mail: adam.obidzinski@polpharma.com	urszula.strzalinska@polpharma.com